#3-06E. Direct Target: IL-23 Signaling in Podocytes and Lupus Nephritis (Arthritis Rheumatol, 2025)

Managing lupus nephritis (LN) remains a clinical challenge due to the toxicity of systemic immunosuppression, necessitating a deeper understanding of local tissue injury. This episode explores a recent study revealing that the Interleukin-23 receptor (IL-23R) is significantly upregulated in the podocytes of patients with LN and lupus-prone mice. The authors demonstrate that IL-23 acts directly on podocytes via the STAT3 pathway, causing actin cytoskeletal disruption and foot process effacement. The most critical discovery is that podocyte-specific deletion of Il23r in mice ameliorated glomerulonephritis and proteinuria without affecting systemic anti-dsDNA antibody levels, suggesting a pathogenic mechanism independent of systemic inflammation. However, critical appraisal is necessary, as the mechanistic proof relies heavily on murine models and the human validation involved a small sample size (n=11). Nevertheless, this study is highly relevant for physicians as it highlights the potential for novel targeted therapies that could preserve renal structure while avoiding the adverse effects of broad systemic immune suppression.

Citation: Fu, R., et al. Podocyte Interleukin-23 Receptor Signaling in the Pathogenesis of Lupus Nephritis. Arthritis & Rheumatology. 2025. DOI: 10.1002/art.43395

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.